Vatalanib (Standard)
Vatalanib (Standard) is the analytical standard of Vatalanib (HY-10203). This product is intended for research and analytical applications. Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 212141-54-3
- Formule: C20H15ClN4
- Masse moléculaire:346.81
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
-
HY-10981
LenvatinibVEGFR/FGFR Inhibitor -
HY-10203
VatalanibVEGFR2/KDR Inhibitor -
HY-10977
TivozanibVEGFR inhibitor -
HY-10260
VandetanibVEGFR2/3 Inhibitor -
HY-10205
CediranibVEGFR2 Inhibitor -
HY-10338
ForetinibMET/VEGFR2/KDR Inhibitor -
HY-10799
EG00229 trifluoroacetateNRP1 Receptor Antagonist -
HY-15458
SAR131675VEGFR3 Inhibitor -
HY-10065
AxitinibTyrosine Kinase Inhibitor -
HY-12018
Vatalanib dihydrochlorideVEGFR2/KDR Inhibitor -
HY-10407
SU 5402Tyrosine Kinase Inhibitor
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 212141-54-3
-
Masse moléculaire 346.81
-
Formule C20H15ClN4
-
SMILES
ClC1=CC=C(C=C1)NC2=NN=C(CC3=CC=NC=C3)C4=C2C=CC=C4
-
Synonyms
PTK787 (Standard); ZK-222584 (Standard); CGP-79787 (Standard)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Wood JM, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60(8 [Content Brief]
[2]. Murakami M, et al. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011, 18(2), 589-596. [Content Brief]
[3]. Wan J, et al. Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone. Oncol Rep. 2016 Mar;35(3):1297-308. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Vatalanib (Standard) Related Classifications
HY-10203R Related Classifications
Powered by Bioz